Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden.

Young A, Palanisamy N, Siddiqui J, Wood DP, Wei JT, Chinnaiyan AM, Kunju LP, Tomlins SA.

Am J Clin Pathol. 2012 Nov;138(5):685-96. doi: 10.1309/AJCPU7PPWUPYG8OH.

2.

Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.

Cornu JN, Cancel-Tassin G, Egrot C, Gaffory C, Haab F, Cussenot O.

Prostate. 2013 Feb 15;73(3):242-9. doi: 10.1002/pros.22563. Epub 2012 Jul 20.

PMID:
22821767
3.

Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.

Leyten GH, Hessels D, Jannink SA, Smit FP, de Jong H, Cornel EB, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, van Oort IM, Mulders PF, Hulsbergen-van de Kaa CA, Schalken JA.

Eur Urol. 2014 Mar;65(3):534-42. doi: 10.1016/j.eururo.2012.11.014. Epub 2012 Nov 15.

PMID:
23201468
4.

Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study.

Lin DW, Newcomb LF, Brown EC, Brooks JD, Carroll PR, Feng Z, Gleave ME, Lance RS, Sanda MG, Thompson IM, Wei JT, Nelson PS; Canary Prostate Active Surveillance Study Investigators.

Clin Cancer Res. 2013 May 1;19(9):2442-50. doi: 10.1158/1078-0432.CCR-12-3283. Epub 2013 Mar 20.

5.

Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy.

Merdan S, Tomlins SA, Barnett CL, Morgan TM, Montie JE, Wei JT, Denton BT.

Cancer. 2015 Nov 15;121(22):4071-9. doi: 10.1002/cncr.29611. Epub 2015 Aug 17.

PMID:
26280815
6.

Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.

Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S, Williamsen S, Hodge P, Meinke J, Blase A, Penabella Y, Day JR, Varambally R, Han B, Wood D, Wang L, Sanda MG, Rubin MA, Rhodes DR, Hollenbeck B, Sakamoto K, Silberstein JL, Fradet Y, Amberson JB, Meyers S, Palanisamy N, Rittenhouse H, Wei JT, Groskopf J, Chinnaiyan AM.

Sci Transl Med. 2011 Aug 3;3(94):94ra72. doi: 10.1126/scitranslmed.3001970.

7.

Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.

Laxman B, Tomlins SA, Mehra R, Morris DS, Wang L, Helgeson BE, Shah RB, Rubin MA, Wei JT, Chinnaiyan AM.

Neoplasia. 2006 Oct;8(10):885-8.

8.

Evaluation of tissue PCA3 expression in prostate cancer by RNA in situ hybridization--a correlative study with urine PCA3 and TMPRSS2-ERG.

Warrick JI, Tomlins SA, Carskadon SL, Young AM, Siddiqui J, Wei JT, Chinnaiyan AM, Kunju LP, Palanisamy N.

Mod Pathol. 2014 Apr;27(4):609-20. doi: 10.1038/modpathol.2013.169. Epub 2013 Sep 27.

9.

Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer.

Dimitriadis E, Kalogeropoulos T, Velaeti S, Sotiriou S, Vassiliou E, Fasoulis L, Klapsas V, Synesiou M, Apostolaki A, Trangas T, Pandis N.

Anticancer Res. 2013 Jan;33(1):191-7.

PMID:
23267145
10.

Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer.

Stephan C, Jung K, Semjonow A, Schulze-Forster K, Cammann H, Hu X, Meyer HA, Bögemann M, Miller K, Friedersdorff F.

Clin Chem. 2013 Jan;59(1):280-8. doi: 10.1373/clinchem.2012.195560. Epub 2012 Dec 4.

11.

Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.

Salami SS, Schmidt F, Laxman B, Regan MM, Rickman DS, Scherr D, Bueti G, Siddiqui J, Tomlins SA, Wei JT, Chinnaiyan AM, Rubin MA, Sanda MG.

Urol Oncol. 2013 Jul;31(5):566-71. doi: 10.1016/j.urolonc.2011.04.001. Epub 2011 May 19.

12.

A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer.

Laxman B, Morris DS, Yu J, Siddiqui J, Cao J, Mehra R, Lonigro RJ, Tsodikov A, Wei JT, Tomlins SA, Chinnaiyan AM.

Cancer Res. 2008 Feb 1;68(3):645-9. doi: 10.1158/0008-5472.CAN-07-3224.

13.

PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance.

Nakanishi H, Groskopf J, Fritsche HA, Bhadkamkar V, Blase A, Kumar SV, Davis JW, Troncoso P, Rittenhouse H, Babaian RJ.

J Urol. 2008 May;179(5):1804-9; discussion 1809-10. doi: 10.1016/j.juro.2008.01.013. Epub 2008 Mar 18.

PMID:
18353398
14.

Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer.

Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA.

Clin Cancer Res. 2007 Sep 1;13(17):5103-8.

15.

Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer.

Rice KR, Chen Y, Ali A, Whitman EJ, Blase A, Ibrahim M, Elsamanoudi S, Brassell S, Furusato B, Stingle N, Sesterhenn IA, Petrovics G, Miick S, Rittenhouse H, Groskopf J, McLeod DG, Srivastava S.

Clin Cancer Res. 2010 Mar 1;16(5):1572-6. doi: 10.1158/1078-0432.CCR-09-2191. Epub 2010 Feb 16.

16.

Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion.

Salagierski M, Schalken JA.

J Urol. 2012 Mar;187(3):795-801. doi: 10.1016/j.juro.2011.10.133. Epub 2012 Jan 15. Review.

PMID:
22245323
17.

Correlation of ERG expression and DNA methylation biomarkers with adverse clinicopathologic features of prostate cancer.

Kron K, Liu L, Trudel D, Pethe V, Trachtenberg J, Fleshner N, Bapat B, van der Kwast T.

Clin Cancer Res. 2012 May 15;18(10):2896-904. doi: 10.1158/1078-0432.CCR-11-2901. Epub 2012 Mar 27.

18.

Comparative evaluation of urinary PCA3 and TMPRSS2: ERG scores and serum PHI in predicting prostate cancer aggressiveness.

Tallon L, Luangphakdy D, Ruffion A, Colombel M, Devonec M, Champetier D, Paparel P, Decaussin-Petrucci M, Perrin P, Vlaeminck-Guillem V.

Int J Mol Sci. 2014 Jul 30;15(8):13299-316. doi: 10.3390/ijms150813299.

19.

Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer.

Furusato B, Gao CL, Ravindranath L, Chen Y, Cullen J, McLeod DG, Dobi A, Srivastava S, Petrovics G, Sesterhenn IA.

Mod Pathol. 2008 Feb;21(2):67-75. Epub 2007 Dec 7.

20.

Urine PCA3 and TMPRSS2:ERG using cancer-specific markers to detect cancer.

Tomlins SA.

Eur Urol. 2014 Mar;65(3):543-5. doi: 10.1016/j.eururo.2012.12.001. Epub 2012 Dec 13. No abstract available.

PMID:
23265385
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk